ALK Archives - Drugs in Context

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease

Daniele Marinelli, Marco Siringo, Giulio Metro, Biagio Ricciuti, Alain J Gelibter

Article Type

Review

Published

12 Oct 2022

ALK-, ROS1- and NTRK-rearranged tumours represent a distinct clinical and molecular entity amongst non-small-cell lung cancer and have the highest frequency amongst young, non-smoker patients. This paper discusses ALK, ROS1 and NTRK-rearranged disease and all the available treatments are evaluated.

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?

Alfredo Addeo MD, Giulio Metro MD

Article Type

Editorial

Published

10 Jul 2018

This editorial describes the therapeutic achievements in the treatment of patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer.